©2019 by Aeonian Pharmaceuticals. All Rights Reserved.

ABOUT

We are a San Francisco Bay Area-based R&D-stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases by addressing the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. 


Our proprietary platform is supported by an extensive intellectual property portfolio, part of which has been obtained by assignment from the Buck Institute of Novato, California, the nation's first independent research facility focused solely on understanding the connection between aging and chronic disease. 

Our lead compounds are novel and highly selective therapeutics modulating the mTORC1 pathway. In contrast, chronic exposure to current mTOR inhibitors leads to off-target inhibition of mTORC2, resulting in deleterious effects on metabolic health and immune function.

 
 

THE AEONIAN TEAM

IAN J. MASSEY, MA, PHD

Chief Development Officer

DAVID A. LOWE, PHD

Chief Scientific Officer

BEN ZADIK

Chief Operations Officer

 

STELIOS T. TZANNIS, MS, PHD

President & CEO

THE ADVISORY TEAM

DUDLEY LAMMING, PHD

Discovered the separate roles of mTORC1 and mTORC2

MUSTAFA SAHIN, MD, PHD

Clinical & Preclinical Research in neurological and neuropsychiatric disorders

DAVID NEAL FRANZ, MD

Clinical Development in neurological and neuropsychiatric disorders

JACQUELINE A. FRENCH, MD

Clinical & Preclinical Research in neurological and neuropsychiatric disorders

 

 "mTORC1 is at the core of many different diseases, and the new medicines we are developing have potential to change the lives of patients..."

Stelios Tzannis

 

GET IN TOUCH